Clinical overview of sorafenib in breast cancer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with metastatic breast cancer. There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell proliferation, cell growth, prevention of apoptosis, tumor invasion and neo-angiogenesis. Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of malignant breast cancer cells. This article reviews previous experiences and current and future development strategies of sorafenib in breast cancer.

Original languageEnglish (US)
Pages (from-to)655-663
Number of pages9
JournalFuture Oncology
Volume6
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Breast Neoplasms
Neoplasms
Mitogen-Activated Protein Kinase Kinases
Extracellular Signal-Regulated MAP Kinases
Receptor Protein-Tyrosine Kinases
Growth
Vascular Endothelial Growth Factor A
sorafenib
Early Diagnosis
Cell Proliferation
Apoptosis
Recurrence
Therapeutics

Keywords

  • Breast cancer
  • Sorafenib
  • Tyrosine kinase inhibitor
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical overview of sorafenib in breast cancer. / Moreno Aspitia, Alvaro.

In: Future Oncology, Vol. 6, No. 5, 05.2010, p. 655-663.

Research output: Contribution to journalArticle

@article{ba82f09e070a4d23a785fbff4881c26a,
title = "Clinical overview of sorafenib in breast cancer",
abstract = "Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with metastatic breast cancer. There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell proliferation, cell growth, prevention of apoptosis, tumor invasion and neo-angiogenesis. Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of malignant breast cancer cells. This article reviews previous experiences and current and future development strategies of sorafenib in breast cancer.",
keywords = "Breast cancer, Sorafenib, Tyrosine kinase inhibitor, VEGF",
author = "{Moreno Aspitia}, Alvaro",
year = "2010",
month = "5",
doi = "10.2217/fon.10.41",
language = "English (US)",
volume = "6",
pages = "655--663",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Clinical overview of sorafenib in breast cancer

AU - Moreno Aspitia, Alvaro

PY - 2010/5

Y1 - 2010/5

N2 - Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with metastatic breast cancer. There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell proliferation, cell growth, prevention of apoptosis, tumor invasion and neo-angiogenesis. Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of malignant breast cancer cells. This article reviews previous experiences and current and future development strategies of sorafenib in breast cancer.

AB - Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with metastatic breast cancer. There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell proliferation, cell growth, prevention of apoptosis, tumor invasion and neo-angiogenesis. Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of malignant breast cancer cells. This article reviews previous experiences and current and future development strategies of sorafenib in breast cancer.

KW - Breast cancer

KW - Sorafenib

KW - Tyrosine kinase inhibitor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=77952502755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952502755&partnerID=8YFLogxK

U2 - 10.2217/fon.10.41

DO - 10.2217/fon.10.41

M3 - Article

C2 - 20465381

AN - SCOPUS:77952502755

VL - 6

SP - 655

EP - 663

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 5

ER -